People: Questcor Pharmaceuticals Inc (QCOR.O)

Summary

Name	Age	Since	Current Position
Virgil Thompson	72	2009	Independent Chairman of the Board
Don Bailey	67	2007	President, Chief Executive Officer, Director
Michael Mulroy	46	2011	Chief Financial Officer, Senior Vice President, General Counsel, Corporate Secretary
Stephen Cartt	50	2012	Chief Operating Officer
David Medeiros	61	2012	Executive Vice President, Chief Technical Officer
David Young	60	2009	Chief Scientific Officer
Mitchell Blutt	55	2010	Independent Director
Neal Bradsher	46	2004	Independent Director
Stephen Farrell		2007	Independent Director
Louis Silverman	53	2009	Independent Director
Scott Whitcup	53	2012	Independent Director
Gregory Gin			IR Contact Officer

» Insider Trading

Biographies

Name	Description
Virgil Thompson	Mr. Virgil D. Thompson is an Independent Chairman of the Board of Questcor Pharmaceuticals Inc. Mr. Thompson joined Board of Directors in January 1996. Since July 2009, Mr. Thompson has served as Chief Executive Officer and director of Spinnaker Biosciences, Inc., a private ophthalmic drug delivery company. Mr. Thompson served as the President, Chief Executive Officer and as a director of Angstrom Pharmaceuticals, Inc. from November 2002 until July 2007. From September 2000 until August 2002, Mr. Thompson was President, Chief Executive Officer and a director of Chimeric Therapies, Inc. From May 1999 until September 2000, Mr. Thompson was President, Chief Operating Officer and a member of the board of directors of Bio-Technology General Corporation, a pharmaceutical company (now Savient Pharmaceuticals, Inc.). Mr. Thompson is also the Chairman of the board of directors of Aradigm Corporation, and is a member of the boards of directors of Savient Pharmaceuticals, Inc. and Soligenix, Inc. Mr. Thompson holds a B.S. degree in pharmacy from the University of Kansas and a J.D. degree from The George Washington University Law School.
Don Bailey	Mr. Don M. Bailey is President, Chief Executive Officer, Director of Questcor Pharmaceuticals Inc. He joined Board of Directors in May 2006. Mr. Bailey was appointed as interim President in May 2007 and was appointed as President and Chief Executive Officer in November 2007. Mr. Bailey has been Chairman of the board of directors of STAAR Surgical Company since April 2005. STAAR Surgical Company is in the development, manufacture, and marketing of minimally invasive ophthalmic products employing proprietary technologies. Broadwood Partners, L.P., a partnership controlled by Neal C. Bradsher, owns approximately 16% of STAAR Surgical. Mr. Bailey was the Chairman of the board of directors of Comarco, Inc. from 1998 until 2007, and was employed by Comarco, where he served as its Chief Executive Officer from 1991 until 2000. Mr. Bailey holds a B.S. degree in mechanical engineering from the Drexel Institute of Technology, an M.S. degree in operations research from the University of Southern California, and an M.B.A. from Pepperdine University.
Michael Mulroy	Mr. Michael H. Mulroy is Chief Financial Officer, Senior Vice President, General Counsel, Corporate Secretary of Questcor Pharmaceuticals Inc., since January 2011. Mr. Mulroy is a member of the Board of Directors of Comarco, Inc., a developer and designer of mobile power adapters. From 2003 to 2011, Mr. Mulroy was employed by the law firm of Stradling Yocca Carlson & Rauth, where he served as a partner from 2004, and represented Questcor and other publicly-traded companies. From 1997 to 2003, Mr. Mulroy was an investment banker at Merrill Lynch and Citigroup. Mr. Mulroy earned his J.D. degree from the University of California, Los Angeles and his B.A. (Economics) from the University of Chicago.
Stephen Cartt	Mr. Stephen L. Cartt is Chief Operating Officer of Questcor Pharmaceuticals Inc. since February 15, 2012. He joined the company in March 2005. He was Executive Vice President and Chief Business Officer of the company. Mr. Cartt was a private consultant from August 2002 until March 2005. From March 2000 through August 2002, Mr. Cartt was the Senior Director of Strategic Marketing for Elan Pharmaceuticals. Prior to that, Mr. Cartt held a variety of R&D and Commercial positions at ALZA Corporation during the period July 1985 to March 2000. Mr. Cartt holds a B.S. degree from the University of California at Davis in biochemistry, and an M.B.A. from Santa Clara University.
David Medeiros	Mr. David J. Medeiros is Executive Vice President, Chief Technical Officer of Questcor Pharmaceuticals Inc. since February 15, 2012. He joined the company in June 2003 as Vice President, Manufacturing. He was the Company’s Senior Vice President, Manufacturing. Prior to joining the company, Mr. Medeiros served as Senior Director, Manufacturing at Titan Pharmaceuticals, Inc. from November 2000 to June 2003. Mr. Medeiros holds a B.S. degree in chemical engineering from San Jose State University, a Master’s degree in chemical engineering from University of California, Berkeley and an M.B.A. from the University of California at Berkeley.
David Young	Dr. David Young, Ph.D., is Chief Scientific Officer of Questcor Pharmaceuticals Inc., since October 2009. He joined the company's Board of Directors in September 2006. Prior to joining Questcor as an executive officer, Dr. Young was a member of the company's board of directors from September 2006 until his commencement of employment with the Company. Dr. Young was President of AGI Therapeutics, Inc. from 2006 to 2009. Previously, Dr. Young was the Executive Vice President of the Strategic Drug Development Division of ICON plc, an international CRO, from 2003 to 2006, and founder and CEO of GloboMax LLC, a contract drug development firm purchased by ICON plc in 2003, from 1997 to 2003. Prior to forming GloboMax, Dr. Young was an Associate Professor at the School of Pharmacy, University of Maryland where he held a number of roles including Director of the Pharmacokinetics and Biopharmaceutics Lab and Managing Director of the University of Maryland-VA Clinical Research Unit. Dr. Young holds a B.S. degree in physiology from the University of California, Berkeley, an M.S. degree in physics from the University of Wisconsin-Madison, a Pharm.D. from the University of Southern California and a Ph.D. in pharmaceutical sciences from the University of Southern California.
Mitchell Blutt	Dr. Mitchell J. Blutt, M.D., is an Independent Director of Questcor Pharmaceuticals, Inc. Dr. Blutt joined Board of Directors in July 2010. Dr. Blutt is the founder and Chief Executive Officer of Consonance Capital, a New York-based private investment firm that is a shareholder of Questcor. Dr. Blutt is also board-certified in Internal Medicine and a Clinical Assistant Professor of Medicine at Weill Cornell Medical College. Prior to founding Consonance Capital in 2005, Dr. Blutt was Executive Partner at JP Morgan Partners, a multi-billion dollar global investment fund, and was responsible for locating, structuring, negotiating and financing acquisitions, private equity and venture capital transactions, primarily in the healthcare industry. Dr. Blutt earned his B.A. and M.D. degrees from the University of Pennsylvania and his M.B.A. from The Wharton School at the University of Pennsylvania. Dr. Blutt completed his residency in Internal Medicine at The New York Hospital/Cornell Medical Center. Dr. Blutt has served on the boards of directors of over thirty healthcare companies, including Cardinal Health, Fisher Scientific, and Somerset Pharmaceuticals.
Neal Bradsher	Mr. Neal C. Bradsher, CFA., is an Independent Director Questcor Pharmaceuticals Inc., since March 2004. He joined Board of Directors in March 2004. Since 2002, Mr. Bradsher has been the founder and President of Broadwood Capital, Inc., a New York-based private investment firm that is a shareholder of Questcor. Mr. Bradsher currently is a director of BioTime, Inc., whose board of directors he joined in July 2009. BioTime is a biotechnology company focused on regenerative medicine, an emerging field of therapeutic product development based on technologies developed in stem cell research. Mr. Bradsher holds a B.A. degree in economics from Yale College and is a Chartered Financial Analyst.
Stephen Farrell	Mr. Stephen C. Farrell, CPA., is an Independent Director of Questcor Pharmaceuticals Inc., since November 2007. He joined Board of Directors in November 2007. Since February 2011, Mr. Farrell has served as Chief Executive Officer of NationsHealth, Inc., a medical equipment and healthcare business process outsourcing company. Mr. Farrell previously served as President of PolyMedica Corporation until PolyMedica was acquired by Medco Health Solutions. During his eight year tenure at PolyMedica, Mr. Farrell served in various positions, including President, Chief Operating Officer, Chief Financial Officer, Chief Compliance Officer, and Treasurer. Mr. Farrell was also Executive Vice President and Chief Financial Officer of Stream Global Services, Inc., a business process outsourcing company with 17,000 employees worldwide. Earlier in his career, Mr. Farrell served as Senior Manager at PricewaterhouseCoopers LLP. Mr. Farrell is a founder of Core Contracting Services, Inc., a start-up environmental remediation and demolition company. Mr. Farrell is currently on the board of directors of Brewster Academy, a college preparatory school. Mr. Farrell holds an A.B. from Harvard University and an M.B.A. from the University of Virginia. Mr. Farrell is also a certified public accountant.
Louis Silverman	Mr. Louis E. Silverman is an Independent Director of Questcor Pharmaceuticals Inc., since November 2009. Mr. Silverman joined Board of Directors in November 2009. Mr. Silverman joined Marina Medical Billing Services as its Chief Executive Officer in August 2009. From August 2008 until August 2009, Mr. Silverman served as Chief Executive Officer of LifeComm, a wireless health services initiative founded by Qualcomm Incorporated. From August 2000 until August 2008, Mr. Silverman served as President and Chief Executive Officer of Quality Systems, Inc., a publicly traded, healthcare information technology company. From May 2005 until June 2008, Mr. Silverman also served as a director of Quality Systems. During his tenure as President, Quality Systems grew from $30 million in revenue to $250 million, and the market capitalization of Quality Systems increased from $42 million to $1.2 billion. Among a host of awards, Forbes magazine recognized Quality Systems as one of its 200 Best Small Companies during each of his eight years with that company. Prior to joining Quality Systems, Mr. Silverman served as the Chief Operating Officer of CorVel Corporation, a worker’s compensation managed care services company. CorVel Corporation was named to the Forbes’ 200 Best Small Companies list during each year of Mr. Silverman’s seven year tenure with that company. Mr. Silverman earned a B.A. from Amherst College and an M.B.A. from Harvard Business School.
Scott Whitcup	Dr. Scott M. Whitcup, M.D., is Independent Director of Questcor Pharmaceuticals, Inc., since February 15, 2012. Dr. Whitcup joined Board of Directors in February 2012. Dr. Whitcup is the Executive Vice President, R&D and Chief Scientific Officer at Allergan. Previously, Dr Whitcup was Senior Vice President and Head of the Ophthalmology Therapeutic Area at Allergan. Dr. Whitcup is on the faculty at the Jules Stein Eye Institute/David Geffen School of Medicine at UCLA and also serves as a Director on the board of directors of Avanir Pharmaceuticals, Inc., and as a member of the Biology Chair’s Council at the California Institute of Technology, or Caltech. Dr. Whitcup graduated from Cornell University Medical College and completed residency training both in internal medicine at UCLA Medical Center and in ophthalmology at the Massachusetts Eye and Ear Infirmary-Harvard Medical School. Dr. Whitcup then received fellowship training in uveitis and ocular immunology at the National Eye Institute at the National Institutes of Health. Prior to coming to Allergan, Dr. Whitcup was Clinical Director of the National Eye Institute, and also served as head of the Clinical Branch and Director of the uveitis and ocular immunology fellowship program. Dr. Whitcup also served as Chair of the NIH Medical Executive Committee. Dr. Whitcup currently directs Allergan’s discovery efforts and the worldwide clinical development programs that include ophthalmology, neurosciences, dermatology, plastic surgery, obesity, and urology. Dr. Whitcup’s laboratory work has focused on inflammatory disease and the role of cell adhesion molecules in the pathogenesis of autoimmune disease. Dr. Whitcup is an author on over 150 scientific articles, book chapters, and a textbook on ocular inflammatory disease. Dr. Whitcup has been the recipient of numerous awards including the Cogan Award from the Association for Research in Vision and Ophthalmology (ARVO).
Gregory Gin

Basic Compensation

Name	Fiscal Year Total
Virgil Thompson	--
Don Bailey	4,546,230
Michael Mulroy	1,749,890
Stephen Cartt	2,298,310
David Medeiros	1,232,560
David Young	1,948,800
Mitchell Blutt	--
Neal Bradsher	--
Stephen Farrell	--
Louis Silverman	--
Scott Whitcup	--
Gregory Gin	--

As Of 30 Dec 2011

Options Compensation

Name	Options	Value
Virgil Thompson	0	0
Don Bailey	150,000	5,113,670
Michael Mulroy	0	0
Stephen Cartt	1,105,509	16,563,500
David Medeiros	941,200	19,747,555
David Young	100,000	3,842,020
Mitchell Blutt	0	0
Neal Bradsher	0	0
Stephen Farrell	0	0
Louis Silverman	0	0
Scott Whitcup	0	0
Gregory Gin	0	0

Insider Trading

Name	Shares Traded	Price
BAILEY DON M	6,634	$42.22
BAILEY DON M	16,150	$41.39
BAILEY DON M	160,000	$5.09
THOMPSON VIRGIL D	5,000	$37.46
THOMPSON VIRGIL D	5,000	$4.75
BAILEY DON M	137,216	$40.40
BAILEY DON M	20,000	$5.09
BAILEY DON M	20,000	$36.70
THOMPSON VIRGIL D	2,187	$4.75
THOMPSON VIRGIL D	2,187	$35.00
BAILEY DON M	10,031	$5.09
BAILEY DON M	10,031	$30.06
BAILEY DON M	9,969	$5.09
BAILEY DON M	9,969	$30.00
THOMPSON VIRGIL D	10,000	$4.75
THOMPSON VIRGIL D	47,500	$35.00
THOMPSON VIRGIL D	7,500	$1.47
THOMPSON VIRGIL D	15,000	$5.77
THOMPSON VIRGIL D	10,000	$1.47
BAILEY DON M	20,000	$32.06
BAILEY DON M	20,000	$5.09
YOUNG DAVID	10,625	$0.00
YOUNG DAVID	10,625	$0.00
MULROY MICHAEL H	18,250	$0.00
BAILEY DON M	71,453	$0.00

» Full list on Insider Trading

People: Questcor Pharmaceuticals Inc (QCOR.O)

Related Topics:

Summary

Biographies

Basic Compensation

Options Compensation

Related Topics: